Archer-Daniels-Midland announced on February 25, 2025, an exclusive distribution agreement with Asahi Group Foods Corporation for its proprietary lactic acid-based postbiotic, Lactobacillus gasseri CP2305. This ingredient is backed by eight human clinical trials and targets stress, mood, and sleep support.
The introduction of this postbiotic into ADM's portfolio addresses a rapidly growing wellness segment, with products targeting mood/relaxation support experiencing a double-digit CAGR of 13% from 2018-2023. ADM will expand distribution of L. gasseri CP2305 to food manufacturers in North America, Europe, and Asia starting in March.
Mark Lotsch, ADM's President of Global Health & Wellness, stated that this agreement is a critical step in advancing new product development to support consumers' quality of life worldwide. As a postbiotic, L. gasseri CP2305 offers formulation flexibility, capable of withstanding tough conditions common in functional foods.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.